RESULTS:
Circulating concentrations of the novel intronic antisense lncRNA TrAnscript Predicting Survival in AKI (TapSAKI) (P Ͻ 0.0001) were detectable in kidney biopsies and upregulated in plasma of patients with AKI. Cox regression and Kaplan-Meier curve analysis revealed TapSAKI as an independent predictor of 28-day survival (P Ͻ 0.01). TapSAKI was enriched in tubular epithelial cells subjected to ATP depletion (P ϭ 0.03).
CONCLUSIONS:
The alteration of circulating concentrations of lncRNAs in patients with AKI supports Tap-SAKI as a predictor of mortality in this patient cohort.
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Acute kidney injury (AKI) 4 in critically ill patients has been identified as an independent risk factor for increased mortality (1 ) . Mortality of patients with AKI in the intensive care unit (ICU) is still unacceptably high despite significant advances in supportive care (2 ) . A recent multinational, multicenter study of 29 000 critically ill patients, including 1700 with AKI, revealed that the in-hospital mortality exceeds 60% (3 ). Thus, detection of patients at particular risk for both death and prolonged kidney failure after AKI in the setting of intensive care medicine and renal replacement therapy (RRT) remains an area of utmost interest.
More than 80% of the human genome is transcribed into RNA transcripts without protein-coding potential (4, 5 ) . These so-called noncoding RNAs (ncRNAs) are arbitrarily separated into long ncRNAs (lncRNAs); (Ն200 nucleotides) and small ncRNAs (Յ200 nucleotides) on the basis of their size. Small RNAs such as microRNAs are currently under intense investigation (6, 7 ) . However, little is known about the functional role of lncRNAs. lncRNAs play a critical role in several important cellular processes, such as the regulation of imprinting and X-chromosome inactivation (8 ) . Emerging studies in the cancer and cardiovascular field have demonstrated that lncRNAs can be detected in body fluids of patients (9, 10 ) .
In the present study we investigated the pattern of circulating lncRNAs in the circulation of critically ill patients with AKI requiring RRT and their potential predictive value concerning outcome. Circulating lncRNAs were assessed in RNA isolated from kidney biopsy and plasma samples of 109 patients with AKI, 30 age-matched healthy controls, and 30 disease controls with acute myocardial infarction (AMI).
Materials and Methods
This study is a post hoc measurement of prospectively collected blood samples from the HANDOUT (Hannover Dialysis Outcome) trial (11 ) . Patients suffering from AKI in 7 ICUs of the tertiary care center at the Hannover Medical School were evaluated for inclusion. The study protocol was approved by the Hannover Medical School Ethics Committee and was conducted in accordance with the Declaration of Helsinki and German Federal Guidelines. The inclusion criteria were nonpostrenal AKI with RRT dependence indicated by the loss of kidney function of Ͼ30% calculated estimated glomerular filtration rate (eGFR) with either the Modification of Diet in Renal Disease (MDRD) or Cockroft-Gault equation and/or cystatin C-GFR within 48 h before inclusion and oliguria/anuria (Ͻ30 mL/h Ͼ6 h before inclusion) or hyperkalemia (Ͼ6.5 mmol/L) or severe metabolic acidosis (pH Ͻ7.15, bicarbonate Ͻ12 mmol/l). Exclusion criteria were preexisting chronic kidney disease as defined by eGFR Ͻ60 mL/min or a serum creatinine concentration Ͼ1.7 mg/dL more than 10 days before initiation of the first RRT. Additionally, we considered the presence of an arteriovenous fistula or dialysis catheter as indicative of chronic kidney disease. Further exclusion criteria were participation in another study, consent denial or withdrawal, and need for extracorporeal membrane oxygenation therapy. Enrollment was performed by attending nephrologists after obtaining written informed consent from a patient or his/her legal representatives. If the patient was recovering and able to communicate, he/she was informed of the study purpose and consent was required to further maintain his/her status as a study participant.
After study inclusion, the specific medical condition leading to RRT initiation was documented for all patients out of a list of 4 possible causes requiring immediate RRT. All patients received a nutritional intake of at least 25-30 kcal/kg per day, preferentially delivered as enteral nutrition. The prescribed protein intake was Ͼ1.2 g/kg per day. RRT in all patients was performed in a slow extended dialysis mode using the GENIUS TM dialysis system (Fresenius Medical Care) as described in detail elsewhere (12 ) . The dose of the RRT was tailored according to the patient's need, starting with at least 1 treatment daily. RRT was discontinued in patients meeting the following criteria for renal recovery: urine output Ͼ1000 mL/day and/or increased solute clearance, i.e., decline in pretreatment serum creatinine concentration with eGFR Ͼ15 mL/min (by MDRD, Cockroft-Gault equation, and/or cystatin C-GFR). Blood was drawn immediately before the start of RRT. Serum creatinine and serum C-reactive protein (CRP) concentrations were determined by an automated analyzer (Beckmann Coulter). Sequential Organ Failure Assessment (SOFA) score (13 ) 
STUDY OUTCOMES AND STATISTICAL ANALYSIS
The main objective of the study was to analyze the predictive value of circulating lncRNAs concerning mortality and renal recovery of critically ill patients with AKI receiving RRT. The study end point was defined as survival 4 weeks after initiation of RRT and renal recovery (no RRT requirement) in survivors 4 weeks after initiation of RRT.
RNA ISOLATION AND lncRNA TRANSCRIPTOME ANALYSIS
Blood samples were collected in EDTA-anticoagulated tubes before initiation of RRT. The blood samples were centrifuged and the plasma removed and stored at Ϫ80°C. The plasma samples were stored in polypropylene tubes (conical bottom; Eppendorf) at a volume of 100 L and thawed immediately before RNA isolation. Total RNA, including small RNAs, was isolated from 100 L of plasma using miRNeasy minicolumns (Qiagen) according to the manufacturer's instructions. As an internal spike-in control, the Caenorhabditis elegans microRNA 39 (cel-miR-39) was added during the isolation process. RNA quantity and quality were measured by NanoDrop ND-1000, and RNA integrity was assessed by standard denaturing agarose gel electrophoresis. We have previously demonstrated the stability of lncRNAs in plasma after repetitive freeze-thaw cycles and subjection to room temperature for up to 24 h (9 ). lncRNA transcriptome analysis was performed using microarraybased global transcriptome analysis (Arraystar human lncRNA microarray; version 2.0), which allowed simulta-neous detection of 33045 lncRNAs. To define a potential good biomarker candidate lncRNA, we chose the following strategy. We first sorted all lncRNA transcripts that were included in the microarrays according to their mean signal intensity. The signal intensity for each lncRNA transcript ranged between 5 (lowest value) and 17 (highest value). For raw lncRNA data normalization and lowintensity filtering, raw signal intensities were normalized using the quantile method by GeneSpring GX v11.5.1, and low-intensity lncRNAs were filtered.
MICROARRAY PROCESSING
The Arraystar Human lncRNA Microarray version 3.0, which is updated from the previous version 2.0, is designed for the global profiling of human lncRNAs and protein-coding transcripts. About 30 586 lncRNAs and 26 109 coding transcripts can be detected by this thirdgeneration lncRNA microarray.
RNA LABELING AND ARRAY HYBRIDIZATION
Sample labeling and array hybridization were performed according to the Agilent One-Color Microarray-Based Gene Expression Analysis Protocol (Agilent Technology) with minor modifications. Briefly, mRNA was purified from total RNA after removal of rRNA (mRNA-ONLY™ eukaryotic mRNA isolation kit; Epicentre). Then, each sample was amplified and transcribed into fluorescent cRNA along the entire length of the transcripts without 3Ј bias utilizing a random priming method. The labeled cRNAs were purified by the RNeasy Mini Kit (Qiagen). The concentration and specific activity of the labeled cRNAs (pmol Cy3/g cRNA) were measured by NanoDrop ND-1000. One microgram of each labeled cRNA was fragmented by adding 5 L of 10X blocking agent and 1 L of 25X fragmentation buffer, and then the mixture was heated at 60°C for 30 min. Finally, 25 L 2X GE hybridization buffer was added to dilute the labeled cRNA. Fifty microliters of hybridization solution was dispensed into the gasket slide and assembled to the lncRNA expression microarray slide. The slides were incubated for 17 h at 65°C in an Agilent hybridization oven. The hybridized arrays were washed, fixed, and scanned using the Agilent DNA microarray scanner according to the manufacturer's instructions. 1 ) was used to analyze acquired array images. Quantile normalization and subsequent data processing were performed using the GeneSpring GX v11.5.1 software package (Agilent Technologies). After quantile normalization of the raw data, lncRNAs and mRNAs with flags indicating at least Present or Marginal ("All Targets Value") in at least 3 out of 9 samples were chosen for further data analysis. Differentially expressed lncRNAs and mRNAs with statistical significance were identified through Volcano Plot filtering between 2 groups of samples. P values were calculated by t-test. Hierarchical clustering was performed using the Agilent GeneSpring GX software (version 11.5.1).
lncRNA VALIDATION
lncRNA sequences were assessed using the ENSEMBL genome browser (ensembl.org) and their detection was next validated by conventional PCR and agarose gel electrophoresis. For this purpose, the isolated RNA was reverse transcribed with random primers (iScript™ Select cDNA synthesis kit; Bio-Rad) using RNA isolated from human kidney biopsy and plasma samples from AKI patients as well as controls. The amounts of RNA used for reverse transcription were 100 ng for plasma and 500 ng for kidney biopsies. Specific lncRNAs were finally amplified by real-time PCR analysis (iQ™ SYBR® Green Supermix, Bio-Rad) in RNA isolated from plasma of patients using primers listed in Table 1 in the Data Supplement that accompanies the online version of this report at http://www.clinchem.org/ 
STATISTICAL ANALYSIS
Continuous variables are expressed as medians with corresponding 25th and 75th percentiles (interquartile 
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Circulating lncRNAs in AKI range) and were compared by using the MannWhitney rank sum test or the Kruskal Wallis 1-way analysis of variance. Categorical variables were compared using the 2 test. Variables were assessed for normal distribution using the Kolmogorov-Smirnov test. Correlations between variables were assessed by the Spearman rank correlation coefficient. Parameters independently associated with survival were identified by univariate and multivariate Cox proportional hazards models. Variables found to be statistically significant at a 10% level in the univariate analysis were included in the multivariate model using backward elimination. Two-sided P values Ͻ0.05 were considered statistically significant for all statistical procedures used. The distribution of the time-to-event variables were estimated using the Kaplan-Meier method with log-rank testing. For comparison of the prognostic values of lncRNAs, ROC curves were generated and the areas under the ROC curves (AUCs) were calculated. All statistical analyses were performed with the SPSS package (SPSS) and GraphPad Prism software (GraphPad Prism Software).
Results

lncRNA EXPRESSION ANALYSIS IN PLASMA
To assess an impact of AKI on circulating lncRNAs, we conducted a genome-wide expression analysis in RNA isolated from plasma of patients with AKI at inception of RRT (n ϭ 3) and healthy age-matched controls (n ϭ 3). Fig. 1 shows that hierarchical clustering analysis (Fig. 1A) and volcano plot analysis (Fig. 1B) clearly distinguished AKI patients from controls as evidenced by a specific signature of significantly regulated circulating lncRNAs. The clinical characteristics of the whole cohort of AKI patients (n ϭ 109) are shown in Table 1 . The concentrations of 4410 circulating lncRNAs were detectable in all groups of the array cohort, showing a signal intensity Ͼ9 and differing between patients and healthy controls. The concentrations of 20 lncRNAs that were upregulated Ͼ5-fold were included for further analysis (see online Supplemental Table 2 ).
lncRNA VALIDATION IN TISSUE AND PLASMA
The detection and amplification of lncRNAs in plasma is challenging because of their low abundance. To investigate the detectability of deregulated circulating lncRNAs, we first amplified transcripts by using RNA isolated from renal biopsy samples of patients (n ϭ 6) by conventional PCR and separated the transcripts by agarose gel electrophoresis. Characteristics of pa- 
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tients included for kidney biopsy are shown in online Supplemental Table 3 . Ten transcripts were found to show specific bands of correct size ( Fig. 2A ). Next, we tested these transcripts in RNA isolated from plasma of patients with AKI and found 3 transcripts to show specific bands (Fig. 2, B and C) . We then performed realtime PCR analysis in a subset of patients with AKI (n ϭ 10). The novel transcript RP5-1104E15.6-001 (ensembl.org) showed clean amplification curves and specific curves in melting curve analysis and was undetectable in water controls without template. Primer sequences of tested lncRNAs and annotation information are given in online Supplemental Table  1 . RP5-1104E15.6-001 is an intronic lncRNA and originates from the gene RP5-1104E15.6 (ensembl.org), which is located on chromosome 22. The transcript runs antisense to ␤-1,4-mannosylglycoprotein 4-␤-N-acetylglucosaminyltransferase (MGAT3). For the sake of clarity we now refer to RP5-1104E15.6-001 as TapSAKI (TrAnscript Predicting Survival in AKI). To ascertain that TapSAKI was specifically detected in plasma, we sequenced transcripts in these patients after PCR amplification, which confirmed that TapSAKI was correctly amplified and detectable in plasma.
TapSAKI IS A BIOMARKER OF AKI
We next investigated TapSAKI in the whole cohort of patients with AKI (n ϭ 109) or AMI (n ϭ 30) and age-matched healthy individuals (n ϭ 30). As shown in Fig. 3A , TapSAKI was significantly increased in these patients compared to healthy controls and disease controls, underlining the specificity as a biomarker in AKI (P Ͻ 0.001). Baseline TapSAKI concentrations were increased in patients with RIFLE stage 3 compared to those with RIFLE stage 1 and 2 (P ϭ 0.001; Fig. 3B ). Baseline TapSAKI concentrations correlated with bicarbonate concentrations (r ϭ 0.3, P ϭ 0.02), leukocyte count (r ϭ 0.4, P Ͻ 0.01), length of need for respirator therapy (r ϭ Ϫ0.3, P ϭ 0.03) and length of stay in the ICU (r ϭ Ϫ0.4, P Ͻ 0.01).
TapSAKI PREDICTS SURVIVAL IN AKI
Patients were grouped as survivors and nonsurvivors at 4 weeks after initiation of RRT. Patient groups were comparable with respect to baseline demographics and the proportion of RIFLE categories (Table 1) . A total of 40 patients died in our cohort. Concentrations of circulating TapSAKI were significantly (P ϭ 0.04) increased in nonsurvivors. To investigate the prognostic potential of circulating TapSAKI concentrations at initiation of RRT with regard to overall mortality, we performed univariate Cox proportional hazards analyses. In our cohort of 109 critically ill patients with AKI TapSAKI concentrations, major surgery, sepsis, shock, APACHE II, and SOFA score showed prognostic significance at a 10% level and were subsequently subjected to mul- tivariate Cox regression analysis (Table 2) . Only APACHE II score (P ϭ 0.007) and TapSAKI concentrations (P ϭ 0.006) remained independent predictors of survival in multivariate analysis. In ROC curve analysis, TapSAKI levels yielded an AUC value of 0.8 (SEM, 0.06; 95% CI, 0.67-0.91; P Ͻ 0.0001).
In ROC curve analysis we defined a cutpoint with 63% sensitivity and 87% specificity (Fig. 3C , a level of 133 relative expression by ⌬⌬Ct analysis). Fig. 3D illustrates the Kaplan-Meier survival curve 4 weeks after initiation of RRT stratified to TapSAKI concentrations above and below the identified cutpoint. Log-rank test confirmed statistical significance for circulating TapSAKI concentrations (P Ͻ 0.01). The used detection algorithm for circulating lncRNAs is given in Fig. 4 .
TapSAKI IS SPECIFICALLY ENRICHED IN HYPOXIC RENAL TUBULAR EPITHELIAL CELLS
To confirm the potential origin of TapSAKI, we assessed its regulation in hypoxic renal endothelial and tubular epithelial cells and found TapSAKI to be specifically enriched in cultured tubular epithelial cells (HK-2) subjected to ATP depletion (P ϭ 0.03; see online Supplemental Fig. 1 ).
Discussion
Our study is the first evaluation of lncRNAs in any cohort of patients with kidney disease. We were able to show that (a) circulating lncRNAs in plasma of critically ill patients with AKI are detectable, (b) circulating TapSAKI concentrations specifically identify patients with AKI, (c) baseline concentrations of TapSAKI correlated with parameters of disease severity, (d) baseline concentrations of circulating TapSAKI are increased in nonsurvivors compared to survivors, (e) TapSAKI is a strong independent prognostic factor for 28-day survival in the multivariate Cox proportional hazards regression analysis and Kaplan-Meier curve analysis, and (f) TapSAKI is enriched in hypoxic tubular epithelial cells. Similar to microRNAs, a stable control or "housekeeping" lncRNA has not been defined in plasma of patients. Concentrations of circulating lncRNAs were therefore normalized to recombinant cel-miR-39, which was supplemented to the plasma samples during the RNA isolation process. This approach was chosen to normalize potential differences in the efficiency of RNA isolation.
Currently, lncRNAs are categorized mainly on the basis of their location with respect to protein-coding genes, because their functional roles are largely unknown. lncRNAs can be categorized as sense, antisense, bidirectional, intronic, or intergenic, depending on their position with regard to protein coding genes (8 ) . lncRNAs are generally characterized by nuclear localization, low level of expression, and sequence conservation and may be polyadenylated (8 ) . In the nucleus, lncRNAs "fine-tune" chromatin architecture by interacting with chromatin remodelling complexes to regulate the expression of genes residing on the same chromosome (in cis) or on another chromosome (in trans) (10 ) . A few lncRNAs have thus far been characterized. lncRNAs play a critical role in the regulation of imprinting, exemplified by the long intergenic RNA Air, and X-chromosome inactivation by X-inactive specific transcript (Xist) (8, 17 ) . Xist, through its cofactor RepA, associates with the polycomb complex and thereby initiates epigenetic silencing during X-chromosome inactivation (8, 18 ) . Air targets repressive histone-modifying activities through molecular interaction with specific chromatin domains to epigenetically silence transcription (8, 19 ) . The first circulating lncRNA, for which assays with clinical utility have been developed, is the prostate cancer associated 3 (non-protein coding) (PCA3) gene, which was found to specifically diagnose patients with prostate cancer (20, 21 ) . Indeed, PCA3 detection in urine was found to show greater specificity for the detection of prostate cancer than the widely accepted prostate-specific antigen test (20, 21 ) . Circulating or urinary lncRNAs may thus be fascinating novel biomarkers that reflect intranuclear processes noninvasively and may therefore be a better estimate of intracellular processes than conventional biomarkers currently established.
We focused on the novel lncRNA transcript TapSAKI, which we identified as a specific biomarker of AKI. TapSAKI is an intronic antisense lncRNA, transcribed from a gene located in the genome on chromosome 22. A specific role for this lncRNA has not been described yet. We here provide evidence of TapSAKI as an independent prognostic survival factor in AKI.
There are several limitations to our study. Importantly, we were unable to provide molecular insights into the underlying mechanisms of TapSAKI release. Additional studies are needed to describe the specific function of TapSAKI within the kidney. Moreover, factors causing a deregulation of circulating lncRNAs in AKI patients are unknown. Hypoxia in tubular epithelial cells might induce changes in TapSAKI expression, as evidenced by our results. Our study represents a single-center experience with a limited number of patients. Larger, independent cohorts are highly desirable to validate our findings. Most patients recruited in our study were patients with severe kidney injury (RIFLE stage 3). It would be desirable to include more patients with mild and moderate kidney injury (RIFLE stage 1 and 2) in future studies.
In conclusion, our study provides first insights into the concentrations of circulating lncRNAs in critically ill patients with AKI. A large number of circulating lncRNAs can be reliably detected in plasma of AKI patients. We identified the novel antisense intronic lncRNA transcript TapSAKI as a strong and independent predictor of survival in critically ill patients with AKI. 
